Idealp-Pharma Launches ‘Hit-To-Candidate’ Services
News Jun 20, 2008
Idealp-Pharma is launching fully integrated drug discovery and preclinical development services combining medicinal chemistry, cheminformatics, screening, early ADMET and preclinical development capabilities to speed up partner’s and client’s small molecules programs from biological target to firstin-man use.
According to Serge Petit, PhD, President and CEO, “Being a one-stop-shop company adds significant value because the lead optimization process involves iterative cycles for incremental optimization. The main advantages of our one-stop-shop service are to have access to all the experimental data, to be able to refocus the synthesis program and then to make the best decision for the lead optimization process in accordance with our customers' specifications.”
“Idealp-Pharma manages its customers' hit discovery and validation, hit-to-lead progression and lead-to-candidate process. Our aim is to deliver chemically and biologically validated hits, accelerating lead optimization and identying IND candidate for our customers”, said Serge Petit.
Postpartum hemorrhaging is the world's leading cause of death for women during and after childbirth, and the third-leading cause in the United States alone. The drug 'misoprostol' although affordable, has dangerous side effects, including uterine cramping, heart attack, toxicity in the brain and spinal cord, fetal death and fetal heart abnormalities. Development of a safer drug may be on the horizon, based on new researchREAD MORE
Global Experts Meeting on Frontiers in Biosimilars and Biologics Congress
Oct 24 - Oct 26, 2019